Log in to save to my catalogue

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or me...

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or me...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2576872643

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

About this item

Full title

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2021-10, Vol.22 (10), p.1468-1482

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundBiliary tract cancers are aggressive, rare, gastrointestinal malignancies with a poor prognosis; approximately half of patients with these cancers survive for less than 1 year after diagnosis with advanced disease. We aimed to evaluate the efficacy and safety of ramucirumab or merestinib in addition to first-line cisplatin–gemcitab...

Alternative Titles

Full title

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2576872643

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2576872643

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(21)00409-5

How to access this item